The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global mRNA Vaccine and Therapeutics Raw Material Market Research Report 2024
Synopsis
The global mRNA Vaccine and Therapeutics Raw Material market was valued at US$ 5047.1 million in 2023 and is anticipated to reach US$ 9934.1 million by 2030, witnessing a CAGR of 10.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for mRNA Vaccine and Therapeutics Raw Material, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Vaccine and Therapeutics Raw Material.
Report Scope
The mRNA Vaccine and Therapeutics Raw Material market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global mRNA Vaccine and Therapeutics Raw Material market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the mRNA Vaccine and Therapeutics Raw Material manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Jena Bioscience
Thermo Fisher Scientific Inc.
SBS Genetech
Sigma Aldrich
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
Etherna
Ethris
Tiba Biotechnology
Product Type Insights
Segment by Type
Infectious Disease Vaccines
Cancer Vaccine
Others
Segment by Application
Hospitals and Clinics
Outpatient and Surgery Centers
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of mRNA Vaccine and Therapeutics Raw Material manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of mRNA Vaccine and Therapeutics Raw Material in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global mRNA Vaccine and Therapeutics Raw Material market was valued at US$ 5047.1 million in 2023 and is anticipated to reach US$ 9934.1 million by 2030, witnessing a CAGR of 10.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for mRNA Vaccine and Therapeutics Raw Material, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Vaccine and Therapeutics Raw Material.
Report Scope
The mRNA Vaccine and Therapeutics Raw Material market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global mRNA Vaccine and Therapeutics Raw Material market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the mRNA Vaccine and Therapeutics Raw Material manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Jena Bioscience
Thermo Fisher Scientific Inc.
SBS Genetech
Sigma Aldrich
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
Etherna
Ethris
Tiba Biotechnology
Product Type Insights
Segment by Type
Infectious Disease Vaccines
Cancer Vaccine
Others
Segment by Application
Hospitals and Clinics
Outpatient and Surgery Centers
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of mRNA Vaccine and Therapeutics Raw Material manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of mRNA Vaccine and Therapeutics Raw Material in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 mRNA Vaccine and Therapeutics Raw Material Market Overview
1.1 Product Overview and Scope of mRNA Vaccine and Therapeutics Raw Material
1.2 mRNA Vaccine and Therapeutics Raw Material Segment by Type
1.2.1 Global mRNA Vaccine and Therapeutics Raw Material Market Value Comparison by Type (2024-2030)
1.2.2 Infectious Disease Vaccines
1.2.3 Cancer Vaccine
1.2.4 Others
1.3 mRNA Vaccine and Therapeutics Raw Material Segment by Application
1.3.1 Global mRNA Vaccine and Therapeutics Raw Material Market Value by Application: (2024-2030)
1.3.2 Hospitals and Clinics
1.3.3 Outpatient and Surgery Centers
1.3.4 Others
1.4 Global mRNA Vaccine and Therapeutics Raw Material Market Size Estimates and Forecasts
1.4.1 Global mRNA Vaccine and Therapeutics Raw Material Revenue 2019-2030
1.4.2 Global mRNA Vaccine and Therapeutics Raw Material Sales 2019-2030
1.4.3 Global mRNA Vaccine and Therapeutics Raw Material Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 mRNA Vaccine and Therapeutics Raw Material Market Competition by Manufacturers
2.1 Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Manufacturers (2019-2024)
2.2 Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Manufacturers (2019-2024)
2.3 Global mRNA Vaccine and Therapeutics Raw Material Average Price by Manufacturers (2019-2024)
2.4 Global mRNA Vaccine and Therapeutics Raw Material Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of mRNA Vaccine and Therapeutics Raw Material, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of mRNA Vaccine and Therapeutics Raw Material, Product Type & Application
2.7 mRNA Vaccine and Therapeutics Raw Material Market Competitive Situation and Trends
2.7.1 mRNA Vaccine and Therapeutics Raw Material Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest mRNA Vaccine and Therapeutics Raw Material Players Market Share by Revenue
2.7.3 Global mRNA Vaccine and Therapeutics Raw Material Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 mRNA Vaccine and Therapeutics Raw Material Retrospective Market Scenario by Region
3.1 Global mRNA Vaccine and Therapeutics Raw Material Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global mRNA Vaccine and Therapeutics Raw Material Global mRNA Vaccine and Therapeutics Raw Material Sales by Region: 2019-2030
3.2.1 Global mRNA Vaccine and Therapeutics Raw Material Sales by Region: 2019-2024
3.2.2 Global mRNA Vaccine and Therapeutics Raw Material Sales by Region: 2025-2030
3.3 Global mRNA Vaccine and Therapeutics Raw Material Global mRNA Vaccine and Therapeutics Raw Material Revenue by Region: 2019-2030
3.3.1 Global mRNA Vaccine and Therapeutics Raw Material Revenue by Region: 2019-2024
3.3.2 Global mRNA Vaccine and Therapeutics Raw Material Revenue by Region: 2025-2030
3.4 North America mRNA Vaccine and Therapeutics Raw Material Market Facts & Figures by Country
3.4.1 North America mRNA Vaccine and Therapeutics Raw Material Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2030)
3.4.3 North America mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe mRNA Vaccine and Therapeutics Raw Material Market Facts & Figures by Country
3.5.1 Europe mRNA Vaccine and Therapeutics Raw Material Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2030)
3.5.3 Europe mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific mRNA Vaccine and Therapeutics Raw Material Market Facts & Figures by Country
3.6.1 Asia Pacific mRNA Vaccine and Therapeutics Raw Material Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2030)
3.6.3 Asia Pacific mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America mRNA Vaccine and Therapeutics Raw Material Market Facts & Figures by Country
3.7.1 Latin America mRNA Vaccine and Therapeutics Raw Material Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2030)
3.7.3 Latin America mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa mRNA Vaccine and Therapeutics Raw Material Market Facts & Figures by Country
3.8.1 Middle East and Africa mRNA Vaccine and Therapeutics Raw Material Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2030)
3.8.3 Middle East and Africa mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global mRNA Vaccine and Therapeutics Raw Material Sales by Type (2019-2030)
4.1.1 Global mRNA Vaccine and Therapeutics Raw Material Sales by Type (2019-2024)
4.1.2 Global mRNA Vaccine and Therapeutics Raw Material Sales by Type (2025-2030)
4.1.3 Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Type (2019-2030)
4.2 Global mRNA Vaccine and Therapeutics Raw Material Revenue by Type (2019-2030)
4.2.1 Global mRNA Vaccine and Therapeutics Raw Material Revenue by Type (2019-2024)
4.2.2 Global mRNA Vaccine and Therapeutics Raw Material Revenue by Type (2025-2030)
4.2.3 Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Type (2019-2030)
4.3 Global mRNA Vaccine and Therapeutics Raw Material Price by Type (2019-2030)
5 Segment by Application
5.1 Global mRNA Vaccine and Therapeutics Raw Material Sales by Application (2019-2030)
5.1.1 Global mRNA Vaccine and Therapeutics Raw Material Sales by Application (2019-2024)
5.1.2 Global mRNA Vaccine and Therapeutics Raw Material Sales by Application (2025-2030)
5.1.3 Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Application (2019-2030)
5.2 Global mRNA Vaccine and Therapeutics Raw Material Revenue by Application (2019-2030)
5.2.1 Global mRNA Vaccine and Therapeutics Raw Material Revenue by Application (2019-2024)
5.2.2 Global mRNA Vaccine and Therapeutics Raw Material Revenue by Application (2025-2030)
5.2.3 Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Application (2019-2030)
5.3 Global mRNA Vaccine and Therapeutics Raw Material Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Jena Bioscience
6.1.1 Jena Bioscience Corporation Information
6.1.2 Jena Bioscience Description and Business Overview
6.1.3 Jena Bioscience mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Jena Bioscience mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.1.5 Jena Bioscience Recent Developments/Updates
6.2 Thermo Fisher Scientific Inc.
6.2.1 Thermo Fisher Scientific Inc. Corporation Information
6.2.2 Thermo Fisher Scientific Inc. Description and Business Overview
6.2.3 Thermo Fisher Scientific Inc. mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Thermo Fisher Scientific Inc. mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.2.5 Thermo Fisher Scientific Inc. Recent Developments/Updates
6.3 SBS Genetech
6.3.1 SBS Genetech Corporation Information
6.3.2 SBS Genetech Description and Business Overview
6.3.3 SBS Genetech mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.3.4 SBS Genetech mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.3.5 SBS Genetech Recent Developments/Updates
6.4 Sigma Aldrich
6.4.1 Sigma Aldrich Corporation Information
6.4.2 Sigma Aldrich Description and Business Overview
6.4.3 Sigma Aldrich mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sigma Aldrich mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.4.5 Sigma Aldrich Recent Developments/Updates
6.5 Moderna Therapeutics
6.5.1 Moderna Therapeutics Corporation Information
6.5.2 Moderna Therapeutics Description and Business Overview
6.5.3 Moderna Therapeutics mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Moderna Therapeutics mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.5.5 Moderna Therapeutics Recent Developments/Updates
6.6 CureVac
6.6.1 CureVac Corporation Information
6.6.2 CureVac Description and Business Overview
6.6.3 CureVac mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.6.4 CureVac mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.6.5 CureVac Recent Developments/Updates
6.7 Translate Bio
6.6.1 Translate Bio Corporation Information
6.6.2 Translate Bio Description and Business Overview
6.6.3 Translate Bio mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Translate Bio mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.7.5 Translate Bio Recent Developments/Updates
6.8 BioNTech
6.8.1 BioNTech Corporation Information
6.8.2 BioNTech Description and Business Overview
6.8.3 BioNTech mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.8.4 BioNTech mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.8.5 BioNTech Recent Developments/Updates
6.9 Sangamo Therapeutics
6.9.1 Sangamo Therapeutics Corporation Information
6.9.2 Sangamo Therapeutics Description and Business Overview
6.9.3 Sangamo Therapeutics mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sangamo Therapeutics mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.9.5 Sangamo Therapeutics Recent Developments/Updates
6.10 Argos Therapeutics
6.10.1 Argos Therapeutics Corporation Information
6.10.2 Argos Therapeutics Description and Business Overview
6.10.3 Argos Therapeutics mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Argos Therapeutics mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.10.5 Argos Therapeutics Recent Developments/Updates
6.11 In-Cell-Art
6.11.1 In-Cell-Art Corporation Information
6.11.2 In-Cell-Art mRNA Vaccine and Therapeutics Raw Material Description and Business Overview
6.11.3 In-Cell-Art mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.11.4 In-Cell-Art mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.11.5 In-Cell-Art Recent Developments/Updates
6.12 Etherna
6.12.1 Etherna Corporation Information
6.12.2 Etherna mRNA Vaccine and Therapeutics Raw Material Description and Business Overview
6.12.3 Etherna mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Etherna mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.12.5 Etherna Recent Developments/Updates
6.13 Ethris
6.13.1 Ethris Corporation Information
6.13.2 Ethris mRNA Vaccine and Therapeutics Raw Material Description and Business Overview
6.13.3 Ethris mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Ethris mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.13.5 Ethris Recent Developments/Updates
6.14 Tiba Biotechnology
6.14.1 Tiba Biotechnology Corporation Information
6.14.2 Tiba Biotechnology mRNA Vaccine and Therapeutics Raw Material Description and Business Overview
6.14.3 Tiba Biotechnology mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Tiba Biotechnology mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.14.5 Tiba Biotechnology Recent Developments/Updates
6.15 Product Type Insights
6.15.1 Product Type Insights Corporation Information
6.15.2 Product Type Insights mRNA Vaccine and Therapeutics Raw Material Description and Business Overview
6.15.3 Product Type Insights mRNA Vaccine and Therapeutics Raw Material Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Product Type Insights mRNA Vaccine and Therapeutics Raw Material Product Portfolio
6.15.5 Product Type Insights Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 mRNA Vaccine and Therapeutics Raw Material Industry Chain Analysis
7.2 mRNA Vaccine and Therapeutics Raw Material Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 mRNA Vaccine and Therapeutics Raw Material Production Mode & Process
7.4 mRNA Vaccine and Therapeutics Raw Material Sales and Marketing
7.4.1 mRNA Vaccine and Therapeutics Raw Material Sales Channels
7.4.2 mRNA Vaccine and Therapeutics Raw Material Distributors
7.5 mRNA Vaccine and Therapeutics Raw Material Customers
8 mRNA Vaccine and Therapeutics Raw Material Market Dynamics
8.1 mRNA Vaccine and Therapeutics Raw Material Industry Trends
8.2 mRNA Vaccine and Therapeutics Raw Material Market Drivers
8.3 mRNA Vaccine and Therapeutics Raw Material Market Challenges
8.4 mRNA Vaccine and Therapeutics Raw Material Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global mRNA Vaccine and Therapeutics Raw Material Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global mRNA Vaccine and Therapeutics Raw Material Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global mRNA Vaccine and Therapeutics Raw Material Market Competitive Situation by Manufacturers in 2023
Table 4. Global mRNA Vaccine and Therapeutics Raw Material Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Manufacturers (2019-2024)
Table 6. Global mRNA Vaccine and Therapeutics Raw Material Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global mRNA Vaccine and Therapeutics Raw Material Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market mRNA Vaccine and Therapeutics Raw Material Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of mRNA Vaccine and Therapeutics Raw Material, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of mRNA Vaccine and Therapeutics Raw Material, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of mRNA Vaccine and Therapeutics Raw Material, Product Type & Application
Table 12. Global Key Manufacturers of mRNA Vaccine and Therapeutics Raw Material, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global mRNA Vaccine and Therapeutics Raw Material by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccine and Therapeutics Raw Material as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global mRNA Vaccine and Therapeutics Raw Material Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global mRNA Vaccine and Therapeutics Raw Material Sales by Region (2019-2024) & (K Units)
Table 18. Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Region (2019-2024)
Table 19. Global mRNA Vaccine and Therapeutics Raw Material Sales by Region (2025-2030) & (K Units)
Table 20. Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Region (2025-2030)
Table 21. Global mRNA Vaccine and Therapeutics Raw Material Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Region (2019-2024)
Table 23. Global mRNA Vaccine and Therapeutics Raw Material Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Region (2025-2030)
Table 25. North America mRNA Vaccine and Therapeutics Raw Material Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2024) & (K Units)
Table 27. North America mRNA Vaccine and Therapeutics Raw Material Sales by Country (2025-2030) & (K Units)
Table 28. North America mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe mRNA Vaccine and Therapeutics Raw Material Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2024) & (K Units)
Table 32. Europe mRNA Vaccine and Therapeutics Raw Material Sales by Country (2025-2030) & (K Units)
Table 33. Europe mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific mRNA Vaccine and Therapeutics Raw Material Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific mRNA Vaccine and Therapeutics Raw Material Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific mRNA Vaccine and Therapeutics Raw Material Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific mRNA Vaccine and Therapeutics Raw Material Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific mRNA Vaccine and Therapeutics Raw Material Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America mRNA Vaccine and Therapeutics Raw Material Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2024) & (K Units)
Table 42. Latin America mRNA Vaccine and Therapeutics Raw Material Sales by Country (2025-2030) & (K Units)
Table 43. Latin America mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa mRNA Vaccine and Therapeutics Raw Material Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa mRNA Vaccine and Therapeutics Raw Material Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa mRNA Vaccine and Therapeutics Raw Material Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa mRNA Vaccine and Therapeutics Raw Material Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global mRNA Vaccine and Therapeutics Raw Material Sales (K Units) by Type (2019-2024)
Table 51. Global mRNA Vaccine and Therapeutics Raw Material Sales (K Units) by Type (2025-2030)
Table 52. Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Type (2019-2024)
Table 53. Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Type (2025-2030)
Table 54. Global mRNA Vaccine and Therapeutics Raw Material Revenue (US$ Million) by Type (2019-2024)
Table 55. Global mRNA Vaccine and Therapeutics Raw Material Revenue (US$ Million) by Type (2025-2030)
Table 56. Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Type (2019-2024)
Table 57. Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Type (2025-2030)
Table 58. Global mRNA Vaccine and Therapeutics Raw Material Price (US$/Unit) by Type (2019-2024)
Table 59. Global mRNA Vaccine and Therapeutics Raw Material Price (US$/Unit) by Type (2025-2030)
Table 60. Global mRNA Vaccine and Therapeutics Raw Material Sales (K Units) by Application (2019-2024)
Table 61. Global mRNA Vaccine and Therapeutics Raw Material Sales (K Units) by Application (2025-2030)
Table 62. Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Application (2019-2024)
Table 63. Global mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Application (2025-2030)
Table 64. Global mRNA Vaccine and Therapeutics Raw Material Revenue (US$ Million) by Application (2019-2024)
Table 65. Global mRNA Vaccine and Therapeutics Raw Material Revenue (US$ Million) by Application (2025-2030)
Table 66. Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Application (2019-2024)
Table 67. Global mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Application (2025-2030)
Table 68. Global mRNA Vaccine and Therapeutics Raw Material Price (US$/Unit) by Application (2019-2024)
Table 69. Global mRNA Vaccine and Therapeutics Raw Material Price (US$/Unit) by Application (2025-2030)
Table 70. Jena Bioscience Corporation Information
Table 71. Jena Bioscience Description and Business Overview
Table 72. Jena Bioscience mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Jena Bioscience mRNA Vaccine and Therapeutics Raw Material Product
Table 74. Jena Bioscience Recent Developments/Updates
Table 75. Thermo Fisher Scientific Inc. Corporation Information
Table 76. Thermo Fisher Scientific Inc. Description and Business Overview
Table 77. Thermo Fisher Scientific Inc. mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Thermo Fisher Scientific Inc. mRNA Vaccine and Therapeutics Raw Material Product
Table 79. Thermo Fisher Scientific Inc. Recent Developments/Updates
Table 80. SBS Genetech Corporation Information
Table 81. SBS Genetech Description and Business Overview
Table 82. SBS Genetech mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. SBS Genetech mRNA Vaccine and Therapeutics Raw Material Product
Table 84. SBS Genetech Recent Developments/Updates
Table 85. Sigma Aldrich Corporation Information
Table 86. Sigma Aldrich Description and Business Overview
Table 87. Sigma Aldrich mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Sigma Aldrich mRNA Vaccine and Therapeutics Raw Material Product
Table 89. Sigma Aldrich Recent Developments/Updates
Table 90. Moderna Therapeutics Corporation Information
Table 91. Moderna Therapeutics Description and Business Overview
Table 92. Moderna Therapeutics mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Moderna Therapeutics mRNA Vaccine and Therapeutics Raw Material Product
Table 94. Moderna Therapeutics Recent Developments/Updates
Table 95. CureVac Corporation Information
Table 96. CureVac Description and Business Overview
Table 97. CureVac mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. CureVac mRNA Vaccine and Therapeutics Raw Material Product
Table 99. CureVac Recent Developments/Updates
Table 100. Translate Bio Corporation Information
Table 101. Translate Bio Description and Business Overview
Table 102. Translate Bio mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Translate Bio mRNA Vaccine and Therapeutics Raw Material Product
Table 104. Translate Bio Recent Developments/Updates
Table 105. BioNTech Corporation Information
Table 106. BioNTech Description and Business Overview
Table 107. BioNTech mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. BioNTech mRNA Vaccine and Therapeutics Raw Material Product
Table 109. BioNTech Recent Developments/Updates
Table 110. Sangamo Therapeutics Corporation Information
Table 111. Sangamo Therapeutics Description and Business Overview
Table 112. Sangamo Therapeutics mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Sangamo Therapeutics mRNA Vaccine and Therapeutics Raw Material Product
Table 114. Sangamo Therapeutics Recent Developments/Updates
Table 115. Argos Therapeutics Corporation Information
Table 116. Argos Therapeutics Description and Business Overview
Table 117. Argos Therapeutics mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Argos Therapeutics mRNA Vaccine and Therapeutics Raw Material Product
Table 119. Argos Therapeutics Recent Developments/Updates
Table 120. In-Cell-Art Corporation Information
Table 121. In-Cell-Art Description and Business Overview
Table 122. In-Cell-Art mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. In-Cell-Art mRNA Vaccine and Therapeutics Raw Material Product
Table 124. In-Cell-Art Recent Developments/Updates
Table 125. Etherna Corporation Information
Table 126. Etherna Description and Business Overview
Table 127. Etherna mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Etherna mRNA Vaccine and Therapeutics Raw Material Product
Table 129. Etherna Recent Developments/Updates
Table 130. Ethris Corporation Information
Table 131. Ethris Description and Business Overview
Table 132. Ethris mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Ethris mRNA Vaccine and Therapeutics Raw Material Product
Table 134. Ethris Recent Developments/Updates
Table 135. Tiba Biotechnology Corporation Information
Table 136. Tiba Biotechnology Description and Business Overview
Table 137. Tiba Biotechnology mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Tiba Biotechnology mRNA Vaccine and Therapeutics Raw Material Product
Table 139. Tiba Biotechnology Recent Developments/Updates
Table 140. Product Type Insights Corporation Information
Table 141. Product Type Insights Description and Business Overview
Table 142. Product Type Insights mRNA Vaccine and Therapeutics Raw Material Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Product Type Insights mRNA Vaccine and Therapeutics Raw Material Product
Table 144. Product Type Insights Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. mRNA Vaccine and Therapeutics Raw Material Distributors List
Table 148. mRNA Vaccine and Therapeutics Raw Material Customers List
Table 149. mRNA Vaccine and Therapeutics Raw Material Market Trends
Table 150. mRNA Vaccine and Therapeutics Raw Material Market Drivers
Table 151. mRNA Vaccine and Therapeutics Raw Material Market Challenges
Table 152. mRNA Vaccine and Therapeutics Raw Material Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of mRNA Vaccine and Therapeutics Raw Material
Figure 2. Global mRNA Vaccine and Therapeutics Raw Material Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global mRNA Vaccine and Therapeutics Raw Material Market Share by Type in 2023 & 2030
Figure 4. Infectious Disease Vaccines Product Picture
Figure 5. Cancer Vaccine Product Picture
Figure 6. Others Product Picture
Figure 7. Global mRNA Vaccine and Therapeutics Raw Material Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global mRNA Vaccine and Therapeutics Raw Material Market Share by Application in 2023 & 2030
Figure 9. Hospitals and Clinics
Figure 10. Outpatient and Surgery Centers
Figure 11. Others
Figure 12. Global mRNA Vaccine and Therapeutics Raw Material Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global mRNA Vaccine and Therapeutics Raw Material Market Size (2019-2030) & (US$ Million)
Figure 14. Global mRNA Vaccine and Therapeutics Raw Material Sales (2019-2030) & (K Units)
Figure 15. Global mRNA Vaccine and Therapeutics Raw Material Average Price (US$/Unit) & (2019-2030)
Figure 16. mRNA Vaccine and Therapeutics Raw Material Report Years Considered
Figure 17. mRNA Vaccine and Therapeutics Raw Material Sales Share by Manufacturers in 2023
Figure 18. Global mRNA Vaccine and Therapeutics Raw Material Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest mRNA Vaccine and Therapeutics Raw Material Players: Market Share by Revenue in 2023
Figure 20. mRNA Vaccine and Therapeutics Raw Material Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global mRNA Vaccine and Therapeutics Raw Material Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Country (2019-2030)
Figure 23. North America mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Country (2019-2030)
Figure 24. United States mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Country (2019-2030)
Figure 27. Europe mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Country (2019-2030)
Figure 28. Germany mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Region (2019-2030)
Figure 35. China mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Southeast Asia mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Country (2019-2030)
Figure 43. Latin America mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Country (2019-2030)
Figure 44. Mexico mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa mRNA Vaccine and Therapeutics Raw Material Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa mRNA Vaccine and Therapeutics Raw Material Revenue Market Share by Country (2019-2030)
Figure 49. Turkey mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE mRNA Vaccine and Therapeutics Raw Material Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of mRNA Vaccine and Therapeutics Raw Material by Type (2019-2030)
Figure 53. Global Revenue Market Share of mRNA Vaccine and Therapeutics Raw Material by Type (2019-2030)
Figure 54. Global mRNA Vaccine and Therapeutics Raw Material Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of mRNA Vaccine and Therapeutics Raw Material by Application (2019-2030)
Figure 56. Global Revenue Market Share of mRNA Vaccine and Therapeutics Raw Material by Application (2019-2030)
Figure 57. Global mRNA Vaccine and Therapeutics Raw Material Price (US$/Unit) by Application (2019-2030)
Figure 58. mRNA Vaccine and Therapeutics Raw Material Value Chain
Figure 59. mRNA Vaccine and Therapeutics Raw Material Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
